CEO OGYX

OGYX | High-Throughput Organ-on-a-Chip Platform

CEO & Co-Founder Opportunity | Deeptech BioEngineering | Drug Discovery

Are you looking for an entrepreneurial opportunity at the intersection of microfluidics, advanced in‑vitro models and drug discovery, with the chance to build a high‑impact deep‑tech spin‑off?

OGYX is developing a cost‑effective, robust and user‑friendly microfluidic Organ‑on‑a‑Chip platform designed for high‑throughput in‑vitro assays in research, drug development and toxicology. Backed by Leitat and a strong technical team, the project is now seeking an entrepreneurial CEO to lead the creation of the spin‑off and drive its commercial and strategic development.

As CEO & Co-Founder, you will lead the venture‑building journey together with the scientific and technical team, shaping the business model, early market traction and fundraising strategy of a company with the potential to become a preferred platform provider in the Organ‑on‑a‑Chip market.

About OGYX

Drug discovery still relies heavily on animal models and conventional in‑vitro systems, both of which often fail to accurately replicate human physiology. This results in poor predictive power, major development inefficiencies and growing ethical and regulatory pressure to reduce animal testing.

Organ‑on‑a‑Chip technologies offer a promising alternative, but current solutions face important limitations: they often compromise essential 2D/3D co‑culture features, require peripheral equipment, or are not well suited for multiplexed high‑throughput readouts and scalable production.

OGYX addresses this challenge with a microfluidic OoC plate designed for high‑throughput screening, compatible with 2D/3D co‑cultures and organoids, and readable with standard multi‑well plate readers. Its design combines biological relevance, usability and manufacturability in a single platform.

Why OGYX

• Novel Organ‑on‑a‑Chip plate combining high‑throughput screening with human‑relevant 2D/3D co‑culture capabilities

• Patent published in 2024: WO2024033549

• Technology designed for scalable production and ease of adoption

• Gravity‑driven microfluidics, avoiding peripheral flow equipment

• Membrane‑free design, reducing complexity and cost

• Compatible with standard plate readers through a design‑for‑detection approach

• Validated models already demonstrated in intestine, cartilage and tendon, with additional models under development including liver and kidney

• Early industry validation and feedback through collaborations with Leitat and ReadyCell / MedTech Barcelona

• The current microfluidic plate validation stage is TRL 7

• Clear roadmap for spin‑off creation, beta testing and commercial operation

Current Founding Team

• Pooya Azizian – Future CTO

• Joan Marc Cabot – Principal Investigator & Advisor Head of Diagnostic Devices Group

The project combines strong technical expertise in microfluidics and OoC systems with institutional backing and venture support from Leitat.

Your Role as CEO & Co-Founder (Next 6 Months)

You will lead OGYX through a critical transition phase focused on:

• Spin‑off creation and shareholder structuring

• Defining the go‑to‑market strategy for CROs, biotech, pharma and research groups

• Validating the business model and pricing logic across standard plates, customized plates and modelling services

• Structuring early commercial traction and beta‑testing strategy

• Leading private fundraising efforts

• Building partnerships with CROs, biotech companies and pharmaceutical players

• Building engagement with regulatory agencies

• Supporting the strategic roadmap toward upscaling, product launch and new application development

The Offer

• Relevant equity as CEO & Co-Founder upon company incorporation

• €6,000 stipend during the validation phase (3 monthly instalments of €2,000)

• Opportunity to access a participative loan of up to €50,000 to finance the first phases of the project

• Access to The Collider venture‑building programme, including:

• Mentors and specialists in biotech, IP, go‑to‑market and fundraising

• Support in spin‑off creation and shareholder structuring

• Access to experts in life sciences and industrial strategy

• International exposure through The Collider ecosystem (4YFN, Mobile World Congress, corporate & investor networks)

• Coworking space in Barcelona (Tech Barcelona – Pier 01)

• Two years of post‑incorporation venture‑builder support, including in‑kind services, community access and portfolio perks

This Opportunity Is for You If

• You are an entrepreneur with experience in biotech, life sciences, deep tech or scientific instrumentation

• Previous experience as founder or co‑founder

• Strong network in pharmaceutical sector

• You understand the dynamics of drug discovery, CROs, pharma or advanced research tools

• Experience in B2B sales, fundraising and strategic partnerships

• Familiarity with platform business models and technology transfer is a strong plus

• You are comfortable bridging science, product and business strategy

• Eligible to work in Spain

• Fluent in English and Spanish, Catalan is a plus.